Net Profit Margin: 16.43%
Is the net profit margin high or low?
The net profit margin of 16.43% is 14% below its 5-year average of 19.19%, near the low end of its 5-year range (12.86%–25.87%).
As of Saturday, June 27, 2026. 2.28% above its 12-month average of 16.06%.
WST Profit Margin
Reported quarterly profit margin; no daily interpolation.
WST Average Net Profit Margin Chart
WST Current vs Average Net Profit Margin Chart
WST Net Profit Margin Metrics
NET PROFIT MARGIN
16.43%
NET PROFIT MARGIN AVG TTM
16.06%
NET PROFIT MARGIN AVG 3Y
17.99%
NET PROFIT MARGIN AVG 5Y
19.19%
NET PROFIT MARGIN AVG 10Y
16.10%
NET PROFIT MARGIN AVG 15Y
12.95%
NET PROFIT MARGIN AVG 20Y
11.48%
CURRENT VS TTM AVG
+2.28%
CURRENT VS 3Y AVG
-8.69%
CURRENT VS 5Y AVG
-14.38%
CURRENT VS 10Y AVG
+2.05%
CURRENT VS 15Y AVG
+26.87%
CURRENT VS 20Y AVG
+43.06%
WST Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| West Pharmaceutical Services, Inc. (WST) | $24.79B | 16.43% | 16.06% | 17.99% | 19.19% |
| Waters Corporation (WAT)vs › | $24.41B | 11.91% | 20.93% | 21.85% | 22.39% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 21.40% | 21.94% | 21.74% | 21.20% |
| Quest Diagnostics Incorporated (DGX)vs › | $23.23B | 9.08% | 8.91% | 9.15% | 11.71% |
| BioNTech SE (BNTX)vs › | $23.07B | -44.73% | -31.89% | 3.77% | 12.08% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 40.61% | 41.73% | 40.84% | 37.71% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -143.55% | -128.24% | -70.25% | -50.87% |
| Incyte Corporation (INCY)vs › | $22.73B | 26.71% | 12.90% | 13.00% | 12.11% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 19.31% | 16.12% | 14.73% | 15.57% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 6.66% | 6.01% | 6.56% | 9.24% |
Margin Comparison
Operating Margin
20.7%
Net Profit Margin
16.4%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The net profit margin for WST stock is 16.43%.
- Is West Pharmaceutical Services, Inc.'s net profit margin high or low?
- The net profit margin of 16.43% is 14% below its 5-year average of 19.19%, near the low end of its 5-year range (12.86%–25.87%).
- What is the TTM average net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The TTM average net profit margin for WST stock is 16.06%.
- What is the 3Y average net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The 3Y average net profit margin for WST stock is 17.99%.
- What is the 5Y average net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The 5Y average net profit margin for WST stock is 19.19%.
- What is the 10Y average net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The 10Y average net profit margin for WST stock is 16.10%.
- What is the 15Y average net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The 15Y average net profit margin for WST stock is 12.95%.
- What is the 20Y average net profit margin for West Pharmaceutical Services, Inc. (WST)?
- The 20Y average net profit margin for WST stock is 11.48%.
WST Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 16.43% |
| 2025-12-31 | 16.41% |
| 2025-09-30 | 17.41% |
| 2025-06-30 | 17.20% |
| 2025-03-31 | 12.86% |
| 2024-12-31 | 17.38% |
| 2024-09-30 | 18.21% |
| 2024-06-30 | 15.85% |
| 2024-03-31 | 16.58% |
| 2023-12-31 | 18.71% |
| 2023-09-30 | 21.58% |
| 2023-06-30 | 20.56% |
| 2023-03-31 | 19.56% |
| 2022-12-31 | 14.54% |
| 2022-09-30 | 17.57% |
| 2022-06-30 | 24.43% |
| 2022-03-31 | 24.15% |
| 2021-12-31 | 20.26% |
| 2021-09-30 | 24.85% |
| 2021-06-30 | 25.87% |
| 2021-03-31 | 22.53% |
| 2020-12-31 | 16.96% |
| 2020-09-30 | 15.01% |
| 2020-06-30 | 17.31% |
| 2020-03-31 | 15.12% |
| 2019-12-31 | 13.45% |
| 2019-09-30 | 12.35% |
| 2019-06-30 | 14.08% |
| 2019-03-31 | 12.50% |
| 2018-12-31 | 12.31% |
| 2018-09-30 | 12.79% |
| 2018-06-30 | 12.53% |
| 2018-03-31 | 10.48% |
| 2017-12-31 | -0.60% |
| 2017-09-30 | 12.79% |
| 2017-06-30 | 9.75% |
| 2017-03-31 | 15.70% |
| 2016-12-31 | 10.23% |
| 2016-09-30 | 9.98% |
| 2016-06-30 | 11.52% |
| 2016-03-31 | 6.10% |
| 2015-12-31 | 9.29% |
| 2015-09-30 | 0.44% |
| 2015-06-30 | 7.73% |
| 2015-03-31 | 9.79% |
| 2014-12-31 | 8.98% |
| 2014-09-30 | 8.71% |
| 2014-06-30 | 10.19% |
| 2014-03-31 | 7.81% |
| 2013-12-31 | 6.89% |
| 2013-09-30 | 7.84% |
| 2013-06-30 | 8.77% |
| 2013-03-31 | 9.34% |
| 2012-12-31 | 6.56% |
| 2012-09-30 | 4.87% |
| 2012-06-30 | 4.80% |
| 2012-03-31 | 9.23% |
| 2011-12-31 | 6.36% |
| 2011-09-30 | 5.76% |
| 2011-06-30 | 6.53% |
| 2011-03-31 | 6.64% |
| 2010-12-31 | 2.17% |
| 2010-09-30 | 6.56% |
| 2010-06-30 | 7.70% |
| 2010-03-31 | 7.21% |
| 2009-12-31 | 6.92% |
| 2009-09-30 | 6.64% |
| 2009-06-30 | 7.55% |
| 2009-03-31 | 6.35% |
| 2008-12-31 | 7.23% |
| 2008-09-30 | 5.19% |
| 2008-08-05 | 10.28% |
| 2008-03-31 | 9.68% |
| 2007-12-31 | 2.34% |
| 2007-09-30 | 5.03% |
| 2007-06-30 | 9.86% |
| 2007-03-31 | 10.29% |
| 2006-12-31 | 6.47% |
| 2006-09-30 | 6.09% |
| 2006-06-30 | 8.62% |
| 2006-03-31 | 8.12% |
| 2005-12-31 | 5.98% |
| 2005-09-30 | 4.30% |
| 2005-06-30 | 7.40% |
| 2005-03-31 | 8.90% |
| 2004-12-31 | 0.30% |
| 2004-09-30 | 3.18% |
| 2004-06-30 | 5.58% |
| 2004-03-31 | 5.24% |
| 2003-12-31 | 13.53% |
| 2003-09-30 | 3.41% |
| 2003-06-30 | 5.46% |
| 2003-03-31 | 3.23% |
| 2002-12-31 | 3.29% |
| 2002-09-30 | 3.43% |
| 2002-06-30 | 4.92% |
Related Metrics
About West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Eric Green